logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11077207 B1

PDFFull Text
Date of Patent:
Aug. 03, 2021

Filed:

Jan. 17, 2018

Gene and cell therapy using cell fusion technology

Applicant:

Curamys Inc., Seoul, KR;

Inventors:

Jung-Joon Sung, Seoul, KR;

Seung-Yong Seong, Seoul, KR;

Hee-Woo Lee, Seoul, KR;

Ki Yoon Kim, Seoul, KR;

Assignee:

CURAMYS INC., Seoul, KR;

Attorney:

MH2 Technology Law Group, LLP

Primary Examiner:

Valarie E Bertoglio

Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 14/005 (2006.01); A61K 35/545 (2015.01); C12N 5/0775 (2010.01); C12N 5/12 (2006.01); C12N 5/0793 (2010.01); C12N 15/85 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61K 35/30 (2015.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/16 (2006.01); C12N 9/24 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 35/30 (2013.01); A61K 35/545 (2013.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); C07K 14/005 (2013.01); C12N 5/0606 (2013.01); C12N 5/0619 (2013.01); C12N 5/0667 (2013.01); C12N 5/0696 (2013.01); C12N 5/12 (2013.01); C12N 5/16 (2013.01); C12N 9/2402 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); C12N 2760/18822 (2013.01); C12N 2760/18833 (2013.01);
Abstract

The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Find Patent Forward Citations

Loading…